Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 43.00p 38.00p 48.00p 43.00p 43.00p 43.00p 12,729 06:30:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.9 -4.3 -45.2 - 39.11

Akers Biosciences Share Discussion Threads

Showing 3776 to 3795 of 4000 messages
Chat Pages: 160  159  158  157  156  155  154  153  152  151  150  149  Older
DateSubjectAuthorDiscuss
10/3/2017
12:51
Notwithstanding that this is a BB - ie not an income statement or similar - what was misleading re #3401 and the posts thereafter?
mcmather
10/3/2017
10:30
"In bookkeeping, accounting, and finance, net sales are operating revenues earned by a company for selling its products or rendering its services. Also referred to as revenue, they are reported directly on the income statement as Sales or Net sales." (wikipedia)Sales are not unit volumes, and it is misleading to suggest they are. Hope that helps.
wigwammer
05/3/2017
07:17
Mcm - the history of this board is largely the history of you ramping AKR at multiples of the current price, evidently selling without telling anyone, and now encouraging others to sell near the all time low with highly unbalanced commentary. What a hero.No one is asking you to restart the ramp machine. But 1) don't report that sales are down when sales are up 50% by purposely confusing it with unit volumes. And 2) if your friend is going to make the suggestion that the issue money isn't arriving, he should take the same care in advising when it has.It is nice that you have both made profits here (dubious, but nice) but I doubt anyone who has followed your advice has. Worth noting, as you dish out further advice.
wigwammer
03/3/2017
15:45
Fully agree Norbus re TAN; never met him but had many communications (emails, phone calls, etc) with him and he always came across well.
mcmather
03/3/2017
08:16
I traded a few 100000's once for a profit ; I've met with Walt and Tom and visited There but for the grace of heavens I did not go in for a %age. Miracles have happened and that is what this company needs if it is not to go bust . Tom was good, but not allowed to do all what was planned with the injection and going NASDAQ. Time will tell
norbus
02/3/2017
15:38
"Err, yes, of course it does. Where did those customers go to and what alternative device did they use and why?"The point is - most of them didn't go anywhere. They would rather pay the 80% premium. Hence, sales +50%, not flatlining as you suggest. Re big picture. Revenues up, valuation near all time lows. I'm paying £1, not the £5+ you and slowbus are on record paying.
wigwammer
02/3/2017
14:37
Err, yes, of course it does. Where did those customers go to and what alternative device did they use and why? I'd certainly be interested in that if I was at some other hospital paying the new 80% price. In addition, and in terms of bigger picture, this has been the company's signature product for near on the past decade and with everything that has been thrown at selling the device over that period, unit sales reduced in 2016 and this in the US where akers are based.
mcmather
02/3/2017
12:16
Yes, sales were up a lot. +50%.Does it make sense to compare 2015 unit sales to 2016 unit sales achieved at an 80% price premium?
wigwammer
02/3/2017
10:00
wigwammer. didn't they double the sale price of each device from Q1 2016? It was certainly a significant increase. Say they increased the price by 80%, using the figure quoted of $1.4m * 80% = $2.52m; ie revenue was up but unit sales would appear to have reduced on that basis?
mcmather
02/3/2017
08:01
"Either way, if you take away the Chinese order which has been in the pipeline for a number of years now, the sales of the signature product, PIFA HIT, flat-lined at best elsewhere (ie the US) in 2016."Appreciate your thoughts but this is not correct. Pifa hep sales 2016 = $2.6m. Minus china order = $2.1m vs $1.4m 2015. Pifa hit sales grew circa 50%. They did not flatline. True, you never get honey out of a wasp. But contrary to earlier suggestion, they did get the issue money. I'm interested at £1. The smitten are on record buying at £5+, got burnt, and are now evidently a bit bitter about it.
wigwammer
01/3/2017
14:37
mcm You never get honey out of a wasp; but don't tell that to the smitten
norbus
01/3/2017
00:37
YE 2015 $2,115,050. Q1 2016 $738,023. Q2 2016 $956,487. Q3 2016 $613,198 Q4 2016 $692,000 circa. Total $3m approx. H1 2016 included $505,380 from the Chinese order. Deduct this from the $3m (total 2016) leaves around $380k. Revenue for 2016 essentially revolved around PIFA HIT. Q1 2016 results included the comment that "Demand for PIFA Heparin/PF4 Rapid Assay withstood the new increased pricing schedule implemented in Q1, reflecting clinical dependence on the test from existing customers". Not 100% on this but was the "increased pricing schedule" for the device just shy of 100%? Either way, if you take away the Chinese order which has been in the pipeline for a number of years now, the sales of the signature product, PIFA HIT, flat-lined at best elsewhere (ie the US) in 2016. Appreciate that Gormally might still get a grip here - the wellness / disposal breath test market could still be interesting - but the evidence currently available suggests that the results for shareholders is no different to that of Mr Mitty.
mcmather
01/3/2017
00:22
wigwammer re #3391; in the Q3 conference call Gormally said he "anticipates" receiving the remainder of the Chinese order in Q4 although there was no conviction in what he was saying at this time; around 11mins 45 secs. The Nasdaq price at the time of the conference call had been trading well over $3 for 3 months plus. The recent TU states "NovoTek has conveyed that it has faced additional regulatory hurdles for pricing in China...NovoTek has informed the Company that it now has key opinion leaders positioned across 90 Chinese hospitals in 12 provinces and that it expects high end-user demand once pricing approvals have been obtained". The latest RNS 16 Feb 2017 re the Wellness patent includes "In addition to targeting professionals, Akers Wellness(TM) intends to start marketing OxiChek(TM) through direct-to-consumer channels during 2017. This will include a television marketing campaign"; ie outlay / expense. A large part of Gormally's remit is to look after the interests of shareholders. The conference call was 14 Nov 2016 and the placing was just 8 weeks later. It must have been inevitable that a placing was necessary and also that funds would be required for programmes (eg Wellness) going in to 2017. Even at a 20% discount to the nasdaq share price at the time (call it $3.30) would have achieved a placing at $2.60. Obviously, there is the possibility that the actual figure ($1.20) was all that those who participated were prepared to pay; ie no great confidence in AKR / AKER? The obvious alternative being that those that did partake in the placing have benefited significantly at the expene of the shareholders on board prior the issue? Gormally might not be as careless as Wally but the end result is, ultimately, still the same for shareholders.
mcmather
27/2/2017
17:23
It appears they collected the issue money, despite fears to the contrary.Strange that the fear of no collection (as opposed to the fact of collection) is considered noteworthy on this unbiased and highly informative board.
wigwammer
27/2/2017
12:21
mcm where is China with 2/3rd of the Qtr gone
norbus
01/2/2017
13:10
Record pifa sales in h2, coupled with a significantly lower cost base ($4.6m vs $7m cash breakeven sales rate) and a near historic low valuation - probably never been a better time to buy.
wigwammer
01/2/2017
07:37
expected profit warning Approximately $0.5 million in sales of these products to China were recorded in 2016. This was significantly below expectations of sales to China in the period as the balance of the $2.5 million order from NovoTek Therapeutics Inc. ("NovoTek"), the Company's exclusive distributor for these products in China, announced in March 2016, has not yet been released. Sad Best salvage as it stands is to sell the flagship product and then file for a class action against the directors and professionals
norbus
22/1/2017
09:29
"If they needed funding - which they clearly did"Perhaps they didn't know if the large Chinese order would materialise. With another $1.5m-$2m in hand perhaps they would not have needed to ask for the money, or could at least have scaled it back.
wigwammer
21/1/2017
09:32
The initial S3 form submitted 24 October 2016 included "On October 18, 2016, the last reported sale price of our common stock on the Nasdaq Capital Market was $3.30 per share". If they needed funding - which they clearly did - then why did Gormally not simply get the funds secured at that time when the share price had been trading above $3 for around 3 months? Even with, say, a hefty 20% discount they could still probably have placed at around $2.50. The proposed placing at $1.20 suggests to me that he is either a "friend of Wally", looking after persons other than current shareholders or that there is little appetite for the stock (ie belief in what he / the management are doing); was it determined whether any of the management took part in the offering?
mcmather
20/1/2017
11:32
Sure.In other news, mid price now down to the usd quote level, and around the issue price.Seems to be a few buyers coming in.
wigwammer
Chat Pages: 160  159  158  157  156  155  154  153  152  151  150  149  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180526 19:40:32